Education
About Us
Working with TipRanks
Follow Us
Galecto (GLTO)
NASDAQ:GLTO
GLTO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.01 - $16.05
Previous CloseN/A
Volume2.41K
Average Volume (3M)64.01K
Market Cap
$4.44M
Enterprise Value-$2.76M
Total Cash (Recent Filing)$11.94M
Total Debt (Recent Filing)$60.00K
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Jul 30, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding1,322,359
10 Day Avg. Volume28,563
30 Day Avg. Volume64,014
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.47
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.62
Enterprise Value/Revenue-1.15
Enterprise Value/Gross Profit20.16
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$10.00Price Target Upside194.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Galecto News
PremiumCompany Announcements
Galecto, Inc. Focuses on Oncology and Liver Diseases
Options Prices
Currently, No data available
---
Ownership Overview
2.56% Insiders
1.41% Mutual Funds
7.56% Other Institutional Investors
87.83% Public Companies and Individual Investors
GLTO FAQ
What was Galecto’s price range in the past 12 months?
Galecto lowest stock price was $2.01 and its highest was $16.05 in the past 12 months.
What is Galecto’s market cap?
Galecto’s market cap is $4.44M.
When is Galecto’s upcoming earnings report date?
Galecto’s upcoming earnings report date is Jul 30, 2025 which is in 47 days.
How were Galecto’s earnings last quarter?
Galecto released its earnings results on May 08, 2025. The company reported -$1.92 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.92.
Is Galecto overvalued?
According to Wall Street analysts Galecto’s price is currently Undervalued.
Does Galecto pay dividends?
Galecto does not currently pay dividends.
What is Galecto’s EPS estimate?
Galecto’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galecto have?
Galecto has 1,322,359 shares outstanding.
What happened to Galecto’s price movement after its last earnings report?
Galecto reported an EPS of -$1.92 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.521%.
Which hedge fund is a major shareholder of Galecto?
Currently, no hedge funds are holding shares in GLTO
Company Description
Galecto
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Technical Analysis
Kazia Therapeutics
―
Oragenics
―
Synaptogenix
―
FOXO Technologies
―
Allarity Therapeutics
―